Abstract
Fifty years ago, Huggins and his colleagues [1,2] established that prostate carcinoma could respond to castration or oestrogen therapy, thereby inaugurating a form of treatment which has not been superseded. This unfortunately is not a reflection of the effectiveness or success of antiandrogen therapy: although most men with metastatic prostate cancer treated with some form of androgen withdrawal therapy show an initial beneficial response of no mean palliative value [3], an almost inevitable relapse of the disease to an androgen-insensitive state leads to death from the progressive cancer [4]. In short, in the last half-century, the annual death rate from prostate cancer has not decreased, and it remains a fatal disease for which no therapy increases survival [5]. Also, as increasing age is the most distinctive or identifiable factor associated with the incidence of prostatic cancer, the improving longevity of Western European and North American male populations will increase the number of sufferers and will continually exacerbate the burden placed on the health services in terms of man-hours and on private or state-borne medical costs [6,7].
Keywords
- Epidermal Growth Factor Receptor
- Androgen Receptor
- Prostate Epithelial Cell
- Androgen Response Element
- Transform Growth Factor Type Beta2
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Huggins C and Hodges CV: Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on advanced carcinoma of the prostate gland. Cancer Res 1941 (1):293–297
Huggins C, Stevens RE and Hodges CV: Studies on prostatic cancer II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941 (43):209–223
Peeling WB and Griffiths K: Endocrine treatment of prostatic cancers. In: Blandy JP and Lytton B (eds) The Prostate. Butterworths, London 1986 pp 188–207
Jordan WB, Blackard CE and Byar DP: Consideration of orchidectomy in the treatment of advanced prostatic carcinoma. Southern Med J 1977 (70):1411–1413
Lepor H, Ross A and Walsh PC: The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 1982 (128):335–340
Carter HB and Coffey DS: The prostate: an increasing medical problem. The Prostate 1990 (16):39–48
Griffiths K, Eaton CL and Davies P: Prostatic cancer: aetiology and endocrinology. Horm Res 1989 (32 Suppl 1):38–43
Eaton CL and Griffiths K: The role of endocrine therapy in prostatic cancer. In: Shalet SM (ed) Endocrine Aspects of Malignancy. Bailliere Tindall, London 1990 pp 85–96
Schulze H and Isaacs JT: Biology and therapy of prostatic cancer. Cancer Surveys 1986 (5):487–503
Bruchovsky N, Lesser B, Van Doom E and Craven S: Hormonal effects on cell proliferation in the rat prostate. Vit Horm 1975 (33):61–100
Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ and Sugimura Y: The endocrinology and developmental biology of the prostate. Endocrine Rev 1987 (8):338–362
Katz AE, Benson MC, Wise GJ, Olsson CA, Bandyk MG, Sawczuk IS, Tomashefsky P and Buttyan R: Gene activity during the early phase of androgen-stimulated rat prostate regrowth. Cancer Res 1989 (49):5889–5894
Isaacs JT: Development and characteristics of the available animal model systems for the study of prostate cancer. In: Coffey DS, Bruchovsky N, Gardner WA, Resnick Ml and Karr JP (eds) Current Concepts and Approaches to the Study of Prostate Cancer. Alan R Liss Inc, New York 1987 pp 513–575
Huot RL and Shain SA: Differential androgen modulation of AXC/SSh rat prostate cancer cell proliferation in vitro and its antagonism by antiandrogen. Cancer Res 1986 (46):3775–3781
Eaton CL and Pierrepoint CG: Epithelial and fibroblastoid cell lines derived from the normal canine prostate. I. Separation and characterization of epithelial and stromal components. The Prostate 1982 (3):277–290
Eaton CL and Pierrepoint CG: Growth of a spontaneous canine prostatic adenocarcinoma in vivo and in vitro: isolation and characterization of a neoplastic prostatic epithelial cell line CPA. The Prostate 1988 (12):129–143
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 1983 (43):1809–1818
Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF: Isolation of a human prostatic carcinoma cell line (DU 145). Int J Cancer 1978 (21):274–281
Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF and Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC3). Invest Urol 1979 (17):16–23
Yamamoto KR: Steroid receptor regulated transcription of specific genes and gene networks. Ann Rev Genet 1985 (19):209–252
Miesfeld RL: The structure and function of steroid receptor proteins. Crit Rev Biochem Mol Biol 1989 (24):101–117
Isaacs JT: Antagonistic effect of androgen on prostatic cell death. The Prostate 1984 (5):545–557
Sonnenschein C, Olea N, Pasanen ME and Soto AM: Negative controls of cell proliferation: human prostate cells and androgens. Cancer Res 1989 (49):3474–3481
Buttyan R, Zakeri Z, Lockshin R and Wolgemuth D: Cascade induction of c-fos, c-myc, and heat shock 70K transcripts during regression of the rat ventral prostate gland. Mol Endocrinol 1988 (2):650–657
Quarmby VE, Beckman WC, Wilson EM and French FS: Androgen regulation of c-myc messenger ribonucleic acid levels in rat ventral prostate. Mol Endocrinol 1987 (1):865–874
Weisz A and Bresciani F: Estrogen induces expression of c-fos and c-myc protooncogenes in rat uterus. Mol Endocrinol 1988 (2):816–824
Weisz A, Cicatiello L, Persico E, Scalona M and Bresciani F: Estrogen stimulates transcription of c-jun protooncogene. Mol Endocrinol 1990 (4):1041–1050
Strawhecker JM, Betz NA, Neades RY, Houser W and Pelling JC: Binding of the 97kDa glucocorticoid receptor to the 5’ upstream flanking region of the mouse c-Ha-ras oncogene. Oncogene 1989 (4):1317–1322
Rijnders AWM, van der Korput JAGM, van Steenbrugge GJ, Romijn JC and Trapman J: Expression of cellular oncogenes in human prostatic carcinoma cell lines. Biochem Biophys Res Commun 1985 (132):548–554
Eaton CL, Davies P and Phillips MEA: Growth factor involvement and oncogene expression in prostatic tumours. J Steroid Biochem 1988 (30):341–345
Treiger B and Isaacs J: Expression of a transfected v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability. J Urol 1988 (140):1580–1586
Nag A and Smith RG: Amplification, rearrangement, and elevated expression of c-myc in the human prostatic carcinoma cell line LNCaP. The Prostate 1989 (15):115–122
Fleming WL, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B, Dodd JG and Matusik RJ: Expression of the c-myc oncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 1986 (46):1535–1538
Buttyan R, Sawczuk IS, Benson MC, Siegal JD and Olsson CA: Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. The Prostate 1987 (11):327–337
Peehl DM, Wehner N and Stamey TA: Activated Kiras oncogene in human prostatic adenocarcinoma. The Prostate 1987 (10):281–289
Viola MV, Fromowitz F, Oravez S, Deb S, Finkel G, Lundy J, Hand P, Thor A and Schlom J: Expression of ras oncogene p21 in prostate cancer. New Engl J Med 1986 (314):133–137
Chesa PG, Rettig WJ, Melamed MR, Old LJ and Niman HL: Expression of p21ras in normal and malignant human tissues: lack of association with proliferation and malignancy. Proc Natl Acad Sci USA 1987 (84):3234–3238
Cooke DB, Quarmby VE, Mickey DD, Isaacs JT and French FS: Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system. The Prostate 1988 (13):263–272
Cooke DB, Quarmby VE, Petrusz P, Mickey DD, Der CJ, Isaacs JT and French FS: Expression of ras proto-oncogenes in the Dunning R3327 rat prostatic adenocarcinoma system. The Prostate 1988 (13):273–287
Varma VA, Austin GE and O’Connell AC: Antibodies to ras oncogene p21 proteins lack immunohistochemical specificity for neoplastic epithelium in human prostate tissue. Arch Pathol Lab Med 1989 (113):16–19
Griffiths K, Davies P, Eaton CL, Harper ME, Turkes A and Peeling WB: Endocrine factors in the initiation, diagnosis and treatment of prostatic cancer. In: Voigt K-D and Knabbe C (eds) Endocrine Dependent Tumours. Raven Press, New York 1991 pp 83–130
Rennie PS, Bowden J-F, Freeman SN, Bruchovsky N, Cheng H, Lubahn DB, Wilson EM, French FS and Main L: Cortisol alters gene expression during involution of the rat ventral prostate. Mol Endocrinol 1989 (3):703–708
Davies P and Rushmere NK: Association of glucocorticoid receptors with prostate nuclear sites for androgen receptors and with androgen response elements. J Mol Endocrinol 1990 (5):117–127
Ciaessens F, Rushmere N, Celis L, Peeters B, Davies P and Rombauts W: Functional characterization of an androgen response element. Biochem Soc Trans 1990 (18):561–562
Brandes D: Retinoic acid receptor and surface markers: models for the study of prostatic cancer cells. In: Murphy GP, Sandberg AA and Karr JP (eds) The Prostatic Cell: Structure and Function. Part B. Alan R Liss Inc, New York 1981 pp 207–228
Boyd D, Beynon L, Chisholm GD and Habib FK: Characterization of the retinol and retinoic acid binding proteins in the human prostate. Cancer Res 1984 (44):5532–5537
Jutley JK, Kelleher J, Whelan P and Mikel J: Cytosolic retinoic acid-binding protein in human prostatic dysplasia and neoplasia. The Prostate 1987 (11):127–132
Morris A, Harper ME, Eaton CL and Davies P: unpublished observations
Halgunset J, Sunde A and Lundmo PI: Retinoic acid (RA): an inhibitor of 5a-reductase in human prostatic cancer cells. J Steroid Biochem 1987 (28):731–736
Jutley JK, Reaney S, Kelleher J and Whelan P: Interactions of retinoic acid and androgens in human prostatic tissue. The Prostate 1990 (16):299–304
Lasnitzki I: Growth pattern of mouse prostate gland in organ culture and its response to sex hormones, vitamin A and 3-methylcholanthrene. NCI Monogr 1963 (12):381–403
McKeehan WL, Adams PS and Rosser MP: Direct mitogenic effects of insulin, EGF, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin but not androgen on normal rat prostate epithelial cells in serum-free, primary cell culture. Cancer Res 1984 (44):1998–2010
Kabalin JN, Peehl DM and Stamey TA: Clonal growth of human prostatic epithelial cells is stimulated by fibroblasts. The Prostate 1989 (14):251–263
Chang S-M and Chung LWK: Interaction between prostatic fibroblast and epithelial cells in culture: role of androgen. Endocrinology 1989 (125):2719–2727
Tenniswood M: Role of epithelial-stromal interactions in the control of gene expression in the prostate: an hypothesis. The Prostate 1986 (9):375–385
Jacobs SC, Story MT, Sasse J and Lawson RK: Characterization of growth factors derived from the rat ventral prostate. J Urol 1988 (139):1106–1110
Matuo Y, Nishi N, Matsui S, Sandberg AA, Isaacs JT and Wada F: Heparin binding affinity of rat prostatic growth factor in normal and cancerous prostates: partial purification and characterization of rat prostatic growth factor in the Dunning tumor. Cancer Res 1987 (47):188–192
Nishi N, Matuo Y and Wada F: Partial purification of a major type of rat prostatic growth factor: characterization as an epidermal growth factor-related mitogen. The Prostate 1988 (13):209–220
Story MT, Jacobs SC and Lawson RK: Epidermal growth factor is not the major growth-promoting agent in extracts of prostatic tissue. J Urol 1983 (130):175–179
Nishi N, Matuo Y, Muguruma Y, Yoshitake Y, Nishikawa K and Wada F: A human prostatic growth factor (hPGF): partial purification and characterization. Biochem Biophys Res Commun 1985 (132):1103–1109
Story MT, Sasse J, Jacobs SC and Lawson RK: Prostatic growth factor: purification and structural relationship to basic fibroblast growth factor. Biochemistry 1987 (26):3843–3849
Story MT, Esch F, Shimasaki S, Sasse J, Jacobs SC and Lawson RK: Amino-terminal sequence of a large form of basic fibroblast growth factor isolated? from human benign hyperplastic tissue. Biochem Biophys Res Commun 1987 (142):702–709
Mydlo JH, Bulbul MA, Richon VM, Heston WDW and Fair WR: Heparin-binding growth factor isolated from human prostatic extracts. The Prostate 1988 (12):343–355
Nishi N, Matuo Y, Kunitomi K, Takenaka I, Usami M, Kotake T and Wada F: Comparative analysis of growth factors in normal and pathologic human prostates. The Prostate 1988 (13):39–48
Chaproniere DM and McKeehan WL: Serial culture of single adult human prostatic epithelial cells in serum-free medium containing low calcium and a new growth factor from bovine brain. Cancer Res 1986 (46):819–824
Crabb JW, Armes LG, Carr SA, Johnson CM, Roberts GD, Bordoli RS and McKeehan WL: Complete primary structure of prostatropin, a prostate epithelial cell growth factor. Biochemistry 1986 (25):4988–4993
Story MT, Livingston B, Baeten L, Swartz SJ, Jacobs SC, Begun FP and Lawson RK: Cultured human prostate-derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor. The Prostate 1989 (15):355–365
Mydlo JH, Michaeli J, Heston WDW and Fair WR: Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma. The Prostate 1988 (13):241–247
Mori H, Maki M, Oishi K, Jaye M, Igarashi K, Yoshida O and Hatanaka M: Increased expression of genes for basic fibroblast growth factor and transforming growth factor type beta2 in human benign prostatic hyperplasia. The Prostate 1990 (16):71–80
Mansson P-E, Adams P, Kan M and McKeehan WL: Heparin-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors. Cancer Res 1989 (49):2485–2494
Jacobs SC, Story MT and Lawson RK: Effect of orchiectomy on rat prostatic growth factor levels. In Benign Prostatic Hyperplasia Vol II. NIH Publication no 87–2881 1987 pp 288–29
Jacobs SC and Story MT: Exocrine secretion of epidermal growth factor by the rat prostate: effect of adrenergic agents, cholinergic agents, and vasoactive intestinal peptide. The Prostate 1988 (13):79–87
Traish AM and Wotiz HH: Prostatic epidermal growth factor receptors and their regulation by androgens. Endocrinology 1987 (121):1461–1467
St-Arnaud R, Poyet P, Walker P and Labrie F: Androgens modulate epidermal growth factor receptor levels in the rat ventral prostate. Mol Cell Endocrinol 1988 (56):21–27
Schuurmans ALG, Bolt J and Mulder E: Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. The Prostate 1988 (12):55–63
Davies P and Eaton CL: Binding of epidermal growth factor by human normal, hypertrophic and carcinomatous prostate. The Prostate 1989 (14):123–132
Fekete M, Redding TW, Comaru-Schally AM, Pontes JE, Connelly RW, Srkalovic G and Schally AV: Receptors for luteinising hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. The Prostate 1989 (14):191–208
Maddy SQ, Chisholm GD, Hawkins RA and Habib FK: Localization of epidermal growth factor receptors in the human prostate by biochemical and immunocytochemicai methods. J Endocrinol 1987 (113):147–153
Fiorelli G, De Bellis A, Longo A, Natali A, Constantini A and Serio M: Epidermal growth factor receptors in human hyperplastic prostate and their modulation by chronic treatment with a gonadotropin-releasing hormone analog. J Clin Endocrinol Metab 1989 (68):740–743
Maddy SQ, Chisholm GD, Busuttil A & Habib FK: Epidermal growth factor receptors in human prostate cancer: correlation with histological differentiation of the tumour. Brit J Cancer 1989 (60):41–44
Eaton CL, France TD, Harper ME and Davies P: Epidermal growth factor and androgen action in normal and neoplastic prostatic cell lines. ARTP Bulletin 1990: in press
Wilding G, Valverius E, Knabbe C and Gelmann EP: Role of transforming growth factor-a in human prostate cancer cell growth. The Prostate 1989 (15):1–12
Connolly JM and Rose DP: Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line. The Prostate 1989 (15):177–186
Fowler JE, Lau JLT, Ghosh L, Mills SE and Mounzer A: Epidermal growth factor and prostatic carcinoma: an immunohistochemical study. J Urol 1988 (139):857–861
McKeehan WL, Adams PS and Fast D: Different hormonal requirements for androgen-independent growth of normal and tumor epithelial cells from rat prostate. In Vitro Cell Dev Biol 1987 (23):147–152
Kyprianou N and Isaacs JT: Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens. Endocrinology 1988 (123):2124–2131
Wilding G, Zugmeier G, Knabbe C, Flanders K and Gelmann E: Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol Cell Endocrinol 1989 (62):79–87
Fernandez-Pol JA, Klos DJ and Grant GA: Purification and biological properties of type beta transforming growth factor from mouse transformed cells. Cancer Res 1986 (46):5153–5161
Shain SA, Lin AL, Koger JD and Karaganis AG: Rat prostate cancer cells contain functional receptors for transforming growth factor-beta. Endocrinology 1990 (126):818–825
Kyprianou N and Isaacs JT: Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens. Endocrinology 1988 (123):2124–2131
Schuurmans ALG, Bolt J and Mulder E: Androgens and transforming growth factor beta modulate the growth response to epidermal growth factor in human prostatic tumor cells (LNCaP). Mol Cell Endocrinol 1988 (60):101–104
McKeehan WL and Adams PS: Heparin-binding growth factor/prostatropin attenuates inhibition of rat prostate tumor epithelial cell growth by transforming growth factor type beta. In Vitro Cell Dev Biol 1988 (24):243–246
Story MT, Baeten LA, Molter MA and Lawson RK: Influence of androgen and transforming growth factor beta on basic fibroblast growth factor levels in human prostate-derived fibroblast cell cultures. J Urol 1990 (143): Abstracts of the AUA 85th Annual Meeting, Abstr 211
Bookstein R, Shew J-Y, Chen P-L, Scully P and Lee W-H: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 1990 (247):712–715
Huang H-J, Yee J-K, Shew J-Y, Chen P-L, Bookstein R, Friedmann T, Lee EY-HP and Lee W-H: Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 1988 (242):1563–1566
Laiho M, DeCaprio JA, Ludlow JW, Livingston DM and Massague J: Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell 1990 (62):175–185
Shain SA and Koger JD: Differences in responsiveness of clonally derived AXC/SSh rat prostate cancer cells to secreted or prototypic mitogens. Cancer Res 1989 (49):3898–3903
Isaacs W, Morton R and Isaacs J: The effects of growth factor inhibitors on androgen induced regrowth of rat ventral prostate. J Urol 1990 (143): Abstracts of the AUA 85th Annual Meeting, Abstr 216
Berns EMJJ, Schuurmans ALG, Bolt J, Lamb DJ, Foekens JA and Mulder E: Antiproliferative effects of suramin on androgen responsive tumour cells. Eur J Cancer 1990 (26):470–474
French FS, Lubahn DB, Brown TR, Simental JA, Quigley C, Yarbrough WG, Tan J, Sar M, Joseph DR, Evans BAJ, Hughes IA, Migeon CJ and Wilson EM: The molecular basis of androgen insensitivity. Rec Prog Horm Res 1990 (46):1–38
Harris SE, Rong Z, Harris MA and Lubahn DB: Androgen receptor in human prostate carcinoma LNCaP/Adep cells contains a mutation which alters the specificity of the steroid-dependent transcriptional activation region. Proc Endocrin Soc 72nd Ann Meet 1990: Abstr 275
Veldscholte J, Voorhorst-Ogink MM, Bolt-de Vries J, van Rooij HCJ, Trapman J and Mulder E: Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochim Biophys Acta 1990 (1052):187–194
Wilding G, Chen M and Gelmann EP: Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. The Prostate 1989 (14):103–115
Olea N, Sakabe K, Soto AM and Sonnenschein C: The proliferative effect of “anti-androgens” on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology 1990 (126):1457–1463
Horoszewicz JS and Murphy GP: An assessment of the current use of human interferons in therapy of urological cancers. J Urol 1989 (142):1173–1180
Matuo Y, Nishi N, Takasuka H, Masuda Y, Nishikawa K, Isaacs JT, Adams PS, McKeehan WL and Sato GH: Production and significance of TGF-beta in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma. Biochem Biophys Res Commun 1990 (166):840–847
Ikeda T, Lioubin MN and Marquardt H: Human transforming growth factor type beta2: production by a prostatic adenocarcinoma cell line, purification, and initial characterization. Biochemistry 1987 (26):2406–2410
Wakefield LM and Sporn MB: Suppression of carcinogenesis: a role for TGF-beta and related molecules in prevention of cancer. In Klein G (ed) Tumor Suppressor Genes. Marcel Dekker Inc, New York 1990 (in press)
Griffiths K: Oestrogens and the prostate. In: Khoury S and Chatelain C (eds) Urology: Cancer of the Prostate. FIIS, Paris 1988 pp 308–322
Buttyan R, Olsson CA, Pintar J, Chang C, Bandyk M, Ng P-Y and Sawczuk IS: Induction of the TRPM-2 gene in cells undergoing programmed death. Mol Cell Biol 1989 (9):3473–3481
Davies P, Eaton CL, France TD and Phillips MEA: Growth factor receptors and oncogene expression in prostate cells. Am J Clin Oncol CCT 1988 (11 Suppl 2):S1-S7
Arman JP and Cvitkovic E: Suramin: a new therapeutic concept. Eur J Cancer 1990 (26):417–418
Davies P, Thomas P and Giles MG: Responses to androgens of rat ventral prostate nuclear androgen-binding sites sensitive and resistant to micrococcal nuclease. The Prostate 1982 (3):439–457
Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS and Berger WH: Synthesis of messenger RNAs for transforming growth factors and the epidermal growth factor receptor by human tumors. Cancer Res 1987 (47):707–712
Hierowski MT, McDonald MW, Dunn L and Sullivan JW: The partial dependency of human prostatic growth factor on steroid hormones in stimulating thymidine incorporation into DNA. J Urol 1987 (138):909–912
Stahler MS, Pansky B and Budd GC: Immunocytochemical demonstration of insulin or insulin-like immunoreactivity in the rat prostate gland. The Prostate 1988 (13):189–198
Carmena MJ, Fernandez MD and Prieto JC: Characterization of insulin receptors in isolated epithelial cells from rat ventral prostate: effect of fasting. Cell Biochem Funct 1986 (4):19–24
Eaton CL: personal communication
Matuo Y, Nishi N, Tanaka H, Sasaki I, Isaacs JT and Wada F: Production of IGF-II related peptide by an anaplastic cell line (AT-3) established from the Dunning prostatic carcinoma of rats. In Vitro Cell Dev Biol 1988 (24):1053–1056
Sitaras NM, Sariban E, Bravo M, Pantazis P and Antoniades HN: Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res 1988 (48):1930–1935
Koutsilieris M, Rabbani SA, Bennett HPJ and Goltzman D: Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J Clin Invest 1987 (80):941–946
Koutsilieris M, Rabbani SA and Goltzman D: Selective osteoblast mitogens can be extracted from prostatic tissue. The Prostate 1986 (9):109–115
Koutsilieris M, Rabbani SA and Goltzman D: Effects of human prostatic mitogens on rat bone cells and fibroblasts. J Endocr 1987 (115):447–454
Simpson E, Harrod J, Eilon G, Jacobs JW and Mundy GR: Identification of a messenger ribonucleic acid fraction in human prostatic cancer cells coding for a novel osteoblast-stimulating factor. Endocrinology 1985 (117):1615–1620
Jinno H, Ueda K, Otaguro K, Kato T, Ito J and Tanaka R: Prostate growth factor in the extracts of benign prostatic hypertrophy. Partial purification and physicochemical characterization. Eur Urol 1986 (12):41–48
Maehama S, Li D, Nanri H, Leykam JF and Deuel TF: Purification and characterization of prostate-derived growth factor. Proc Natl Acad Sci USA 1986 (83):8162–8166
Konig JJ, Romijn JC and Schroder FC: Prostatic epithelium inhibiting factor (PEIF): organ specificity and production by prostatic fibroblasts. Urol Res 1987 (15):145–149
Chackal-Roy M, Niemeyer C, Moore M and Zetter BR: Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J Clin Invest 1989 (84):43–50
Klose AG, Bencuya PS and Mickey DD: In vitro growth inhibition of Dunning rat prostate tumor by bone marrow factor. The Prostate 1987 (10):179–188
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Davies, P. (1992). Growth Regulatory Networks in the Prostate. In: Sporn, M.B. (eds) Control of Growth Factors and Prevention of Cancer. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77383-9_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-77383-9_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-77385-3
Online ISBN: 978-3-642-77383-9
eBook Packages: Springer Book Archive